Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression | Zendy

Jorge A. Quiroz | Zendy; Paul Tamburri | Zendy; Dennis Deptula | Zendy; Ludger Banken | Zendy; Ulrich Beyer | Zendy; Michael Rabbia | Zendy; Nikhat Parkar | Zendy; Paulo Fontoura | Zendy; Luca Santarelli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression

Author(s) -

Jorge A. Quiroz,

Paul Tamburri,

Dennis Deptula,

Ludger Banken,

Ulrich Beyer,

Michael Rabbia,

Nikhat Parkar,

Paulo Fontoura,

Luca Santarelli

Publication year - 2016

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2016.0838

Subject(s) - clinical global impression , major depressive disorder , placebo , medicine , adverse effect , serotonin reuptake inhibitor , depression (economics) , adjunctive treatment , randomized controlled trial , global assessment of functioning , antidepressant , clinical endpoint , hamilton rating scale for depression , psychiatry , psychology , mood , alternative medicine , macroeconomics , pathology , hippocampus , economics , body mass index

Antagonism of the postsynaptic metabotropic glutamate subtype 5 receptor is a novel approach to modulate glutamatergic function and has proven efficacy in a number of preclinical behavioral models of depression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research